Ray French Research Governance Manager, ACCORD.

Slides:



Advertisements
Similar presentations
Research Policy & Management RACD INTRODUCTION TO RESEARCH GOVERNANCE.
Advertisements

Good Clinical Practice in Research Clinical Trial Regulations
Good Medical Practice Evidence to use for Appraisal Good Medical Practice 2006.
ROLE OF THE PHYSICIAN IN THE APPROVAL PROCESS Stephanie de Bono MD PhD Medical Advisor, Eli Lilly.
New Trials If you are seeking a collaboration with the UCL CCTU we require you to apply: At least 3 months before the application deadline By using the.
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Good Clinical Research Practice Guidelines For Informed Consent Presented by Catherine May Acting Research Practice Development Officer The Office of Research.
Research Governance in Practice
Good Clinical Practice in Research
IAEA International Atomic Energy Agency Responsibility for Radiation Safety Day 8 – Lecture 4.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
ICH GCP, the MHRA and PATHOLOGY PATHOLOGY QUALITY ASSURANCE Rob Wosley MRQA SEPTEMBER 2009.
Subject Selection and Recruitment David Wendler Department of Clinical Bioethics NIH, USA.
Responsible Sponsorship A case study Dr Birgit Whitman, Head of Research Governance.
John Naim, PhD Director Clinical Trials Research Unit
Managing Sponsorship Research Services University of Oxford.
Research Ethics-Integrity-Governance. University Initiative:The Catalyst? ‘02 Good Research Practice Standards & Procedure to Investigate Potential Research.
Research Ethics & Governance
Good Clinical Practice GCP
Overview of Good Clinical Practices (GCPs)
Applying to a Research Ethics Committee
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
Retha Britz Copyright 2013 All rights reserved for this presentation 1 Establishment and functioning of a REC Retha Britz.
Andrew Thornton, Chairman, RAH HREC
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
The work of the Research Ethics Committee Dr Carol Chu.
“What’s Ethics Got To Do With It” Presentation to the Canberra Evaluation Forum Gary Kent Head Governance Australian Institute of Health and Welfare.
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
Cardiff and Vale UHB Bwrdd lechyd Prifysgol Caerdydd a’r Fro NHS R&D Overview How to avoid the common pitfalls? Thomas Fairman Research Liaison Manager.
Prime Responsibility for Radiation Safety
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
R&D – a perspective Dr Nana Theodorou Research Coordinator Sheffield Clinical Research Office.
14 June 2011 Michael Wright Clinical Governance Team, Department of Health The Responsible Officer: Moving Forward.
Accessing the NHS for Research – NHS R&D Permissions Jemma Hughes R&D Manager ABMU Health Board.
Lifespan GOOD CLINICAL PRACTICE Record Management GCP May 2005.
8 th November 2007 Research: ethics and research governance Rossana Dowsett Research and Regional Development Division [Pre Award Support] University of.
New from 2013… to 2017 Declaration of Helsinki 2013 Updated definition of Critical Audit Finding from HRA April 2014 European Regulation 2014 Care Act.
GCP (GOOD CLINICAL PRACTISE)
Site Set-up and Conduct Caroline O’Leary and Carrie Bayliss.
Combining the strengths of UMIST and The Victoria University of Manchester Ethics in non-medical research Karen Schafheutle PhD Research Practice and Governance.
Responsibilities of Sponsor, Investigator and Monitor
Briefing on MHRA routine inspection of non-commercial clinical trials
CLINICAL TRIALS.
Our Ethical Review Process
Responsibilities of Sponsor, Investigator and Monitor
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Methotrexate in Psoriasis Shared Care Guidelines
Administering Informed Consent Issues for Discussion
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Good Clinical Practice
Research Ethics: a short guide for Staff 2017/18
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Navigating Research Governance, Ethics and Sponsorship
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
And don’t forget… ethics and R&D
Information Governance
Lynne MacRae Research Practice Governance Manager
Research Ethics Committees
Recording Clinical Data
Navigating Research Governance, Ethics and Sponsorship
Good Clinical Practice in Research
Ethics and governance in drugs research
ACCORD UPDATE EVENTS 2019 Sponsorship and R&D
Research, Experimentation, & Clinical Trials
Evidence to use for Appraisal Good Medical Practice 2006
Patient information sheet & Principles of Good Clinical Practice
Multijurisdictional FAQs (Workshop Stream 3)
Protocol Approval Criteria
Presentation transcript:

Ray French Research Governance Manager, ACCORD. SPONSORSHIP Ray French Research Governance Manager, ACCORD.

Evolution of Research Governance 1930s A mistake in a children’s syrup caused a number of deaths and led the FDA (US) to set up a product authorisation system. 1947 Nuremburg Code (Directives for Human Experimentation) 1950s Japanese government regulated sale of medicinal products 1960s Effects of thalidomide synthetic drug triggered review of practices in Europe 1964 Declaration of Helsinki 1968 Medicines Act (UK) 1989 WHO produced action plans for regulation of medical research 1990 First ICH meeting held between EU, Japan and US to harmonise practices 1996   ICH Guideline on Good Clinical Practice (GCP) 1998 Data Protection Act 2000 Adults with Incapacity (Scotland) Act 2000 2001 EU Directive on Clinical Trials (2001/20/EC) 2001 Research Governance Framework for Health and Social Care (UK) 2002 Medical Device Regulations (UK) 2004 Medicines for Human Use (Clinical Trials) Regulations 2004 (UK) 2004 Human Tissue Act 2005 EU Directive on Good Clinical Practice  (2005/28/EC) 2006 Research Governance Framework for Health & Community Care (Scotland) 2007 National Research Ethics Service (NRES) launches 2009 Integrated Research Application System (IRAS) launches 2010 Academy of Medical Sciences (AMS) reviews UK medical research regulation and recommends a number of changes 2011 Health Research Authority established to deliver the principles prescribed by AMS 2017 UK Policy Framework for Health and Social Care Research

A Sponsor is… “…the individual, organisation or partnership that takes on overall responsibility for proportionate, effective arrangements being in place to set up, run and report a research project. All health and social care research has a sponsor. The sponsor is normally expected to be the employer of the chief investigator in the case of non-commercial research or the funder in the case of commercial research.” [UK Policy Framework for Health and Social Care Research 2017]

Not… © Ray French / movingstills.co.uk

But maybe…

PRINCIPLES: Principle 1: Safety Principle 2: Competence Principle 3: Scientific and Ethical Conduct Principle 4: Patient, Service User and Public Involvement Principle 5: Integrity, Quality and Transparency Principle 6: Protocol Principle 7: Legality Principle 8: Benefits and Risks Principle 9: Approval Principle 10: Information about the Research Principle 11: Accessible Findings Principle 12: Choice Principle 13: Insurance and Indemnity Principle 14: Respect for Privacy Principle 15: Compliance

PRINCIPLES: Principle 16: Justified Intervention **Principles that apply to interventional health and social care research** In addition to the principles above, the following principles apply to interventional research only, i.e. where a change in treatment, care or other services is made for the purpose of research: Principle 16: Justified Intervention “adequately supported by the available information (including evidence from previous research)” Principle 17: Ongoing Provision of Treatment “…explain the special arrangements, if any, after the research intervention period has ended (e.g. continuing or changing the treatment…introduced for the purposes of the research).”

PRINCIPLES: Principle 18: Integrity of the Care Record **Principles that apply to interventional health and social care research** In addition to the principles above, the following principles apply to interventional research only, i.e. where a change in treatment, care or other services is made for the purpose of research: Principle 18: Integrity of the Care Record “All information about treatment…provided as part of the research project… is recorded and stored [so] that it can be understood by others involved in the participant’s care….” Principle 19: Duty of Care “The duty of care owed by health and social care providers continues to apply when their patients and service users take part in research….If an unmanageable conflict arises between research and patient interests, the duty to the participant as a patient prevails.”

When is a Sponsor required? All research falling under the remit of the Secretary of State for Health must have a formal sponsor. This includes all research in health and social care that involve NHS patients, their tissue or their information (data). Similar requirements for research involving social care practitioners, clients and resources, where this falls under the Secretary of State for Health’s remit. Any research outside the NHS should also have a sponsor to take on the specific responsibilities of the role.

When is a Sponsor required? (contd.) If… You are a University of Edinburgh or NHS Lothian employee, or a UoE student Your research involves humans, their tissue or data, …contact ACCORD for confirmation of sponsorship of your research before the submission for any other approvals. Sponsorship must be in place before e.g. REC favourable opinion, MHRA authorisation, NHS R&D Management Approval are sought.

Sponsorship in practise. Both the University of Edinburgh and NHS Lothian can act as single sponsors. Single Sponsorship for UoE arises where no NHS patients, staff or facilities are involved. Obvious example: international studies. But NHS Lothian R&D staff still provide (eg) monitoring and QA functions. However, most clinical research is co-sponsored by NHS/UoE through a framework agreement (nb. co-sponsorship is different from joint sponsorship). NHS R&D departments also have a role in providing R&D (aka ‘management’) approval – see Kenny’s presentation. A sponsor can delegate specific responsibilities to any other individual or organisation (needs to be formally agreed and documented).

Sponsor Review. A Sponsor Representative is assigned from the lead Sponsor organisation. Draft documentation is submitted by the CI to ACCORD. Documentation should include as a minimum: Protocol Participant information sheet Informed consent form IRAS form Recruitment material, advertisements, GP letters…. IRAS* form can be quite daunting, and certain sections (eg Lead Sponsor contact details, insurance and indemnity details) may not have obvious answers. If in doubt, leave blank and your Sponsor Rep will advise. * www.myresearchproject.org.uk

Sponsorship Review (contd). Sponsor Rep undertakes review (collates comments from the non-lead Sponsor if study is co-sponsored). Comments back to CI within ca. 10 working days of receipt of documentation. Review comments take the form of a Word document; CI responses can be annotated to it. May be more than one comment-response cycle between Sponsor Rep and CI. Review will confirm the Sponsorship position and the required permissions for the study to commence. Review will anticipate possible comments from the REC and MHRA and will advise on these.

Sponsorship Review (contd). Review may identify need for additional submissions relating to privacy and confidentiality (CAG/PBPP and GDPR requirements) use of radioisotopes (ARSAC) use of human tissue, stem cells (HTA, HFEA) Review will confirm the need (or otherwise) for a formal Risk Assessment Mandatory for CTIMPs, FIH and regulated device studies May also be considered appropriate for other, higher-risk studies Review will also identify requirements for formal agreements and liaise with Research Support Office to initiate those Review will confirm Insurance and Indemnity position for the study

? Questions at the end after Kenny’s presentation…